Michael Yang, ViaCyte CEO
June 25, 2021 11:30 AM EDTUpdated June 28, 09:40 AM
R&D

Af­ter years of fail­ure, Vi­a­Cyte shows off first proof-of-con­cept for di­a­betes stem cell trans­plants

Jason Mast

Editor

Sev­en years af­ter they first tried it, Vi­a­Cyte fi­nal­ly has da­ta show­ing that their stem cell treat­ment for di­a­betes — a po­ten­tial cure — can work in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times